Education
Learn with us
Advocacy
Discover your voice
Connection
Get involved! Serve on a team
AzPA Pharmacy Flash
- FDA approves first intratumoral injection to treat non-metastatic mast cell tumors in dogsThe U.S. Food and Drug Administration approved Stelfonta (tigilanol tiglate injection) to treat dogs with non-metastatic, skin-based (cutaneous) mast cell tumors (MCTs). The FDA is also approving Stelfonta to treat non-metastatic MCTs located under the dog’s skin (subcutaneous), in particular areas of a dog’s leg. Stelfonta is injected directly into the MCT (intratumoral injection). Stelfonta […]
- PD-L1 IHC 22C3 pharmDx gets FDA approval as companion diagnostic for pembrolizumab in breast cancerThe FDA has approved the PD-L1 IHC 22C3 pharmDx to aid in the identification of patients with triple-negative breast cancer (TNBC) who are eligible to receive the PD-1 inhibitor pembrolizumab (Keytruda), according to an announcement from Agilent Technologies, Inc. Previously, the test had also been approved to identify PD-L1 positivity in patients with non–small cell […]
- Pharmacy groups welcome pharmacists elected to U.S. CongressPharmacy groups welcomed incoming members of Congress — including three who are pharmacists — after the United States election. They also stressed pharmacy-centered issues for Congress to focus on when they reconvene in January. “We’re excited Rep. Buddy Carter (R-GA) is being joined in Congress by another pharmacist, Diana Harshbarger of Tennessee, and pharmacy owner […]
